Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BD Announces Fourth Fiscal Quarter And Full Year 2021 Results; Issues Fiscal Year 2022 Guidance

      - Fourth fiscal quarter revenues of $5.1 billion grew 7.3% on a reported basis or 5.9% on a currency-neutral basis.

      - Fiscal 2021 full-year revenues of $20.2 billion grew 18.3% on a reported basis or 15.6% on a currency-neutral basis.

      - Fourth fiscal quarter GAAP diluted earnings per share (EPS) increased 133.3% to $0.84; adjusted diluted EPS decreased 7.2% to $2.59.

      - Fiscal 2021 full-year GAAP diluted EPS increased 152.8% to $6.85; adjusted diluted EPS increased 28.2% to $13.08.

      - BD issues fiscal 2022 guidance of $19.3 to $19.5 billion in revenues and $12.30 to $12.50 adjusted diluted EPS; includes base business revenue growth of 5% to 6% on a currency-neutral basis with improved margin profile.

      - BD announced its 50th consecutive year of dividend increases; dividend raised 4.8%.

      (PRNewsfoto/BD (Becton, Dickinson and Compa)

      News provided by

      BD (Becton, Dickinson and Company)

      Nov 04, 2021, 06:00 ET

      Share this article

      Share this article


      FRANKLIN LAKES, N.J., Nov. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021.

      "Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience of BD's portfolio in even the most uncertain health care environments," said Tom Polen, chairman, CEO and president of BD.  "We also took a number of critical steps this year to lay the foundation for the next phase of our growth, which included strengthening our balance sheet and cash flows, increasing our investments into higher-growth spaces, and stepping up our pace of tuck-in M&A activity.  With increasing momentum in our base business and a clear path to accelerate margin recovery in fiscal 2022 and beyond, we are well-positioned to deliver on our commitments and drive long-term growth and value for all stakeholders."

      Fourth Fiscal Quarter 2021 Operating Results



      Three Months Ended September 30,


      Growth


      Foreign Currency
      Neutral Growth1

      ( Millions of dollars, except per share amounts)


      2021


      2020



      Revenues


      $

      5,135



      $

      4,784



      7.3

      %


      5.9

      %

      Reported Diluted Earnings per Share


      $

      0.84



      $

      0.36



      133.3

      %


      138.9

      %

      Adjusted Diluted Earnings per Share1


      $

      2.59



      $

      2.79



      (7.2)

      %


      (6.5)

      %

      1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

      Geographic Results

      Revenues (Millions of dollars)


      Three Months Ended September 30,


      Reported
      Change


      Foreign Currency
      Neutral Change1



      2021


      2020



      United States


      $

      2,803



      $

      2,752



      1.9

      %


      1.9

      %










      International


      $

      2,331



      $

      2,032



      14.7

      %


      11.3

      %

      1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

      Segment Results
      Fourth fiscal quarter revenue growth across the segments was driven by strong base business performance. 

      Revenues (Millions of dollars)


      Three Months Ended September 30,


      Reported
      Change


      Foreign Currency
      Neutral Change1



      2021


      2020



      BD Medical


      $

      2,532



      $

      2,318



      9.2

      %


      7.7

      %










      BD Life Sciences


      $

      1,532



      $

      1,488



      2.9

      %


      1.5

      %










      BD Interventional


      $

      1,071



      $

      978



      9.5

      %


      8.3

      %

      1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

      In BD Medical, Medication Delivery Solutions revenue growth primarily reflects improved utilization and continued strong demand in the U.S. for catheters and vascular care products.  Performance in Medication Management Solutions primarily reflects growth in infusion sets in the U.S. amid the Delta variant surge, offset by an as expected decline in international infusion pump sales due to high demand in the prior year, particularly in Europe.  Diabetes Care revenue growth benefited from the timing of revenues and slightly better market demand. Pharmaceutical Systems revenues reflect continued strong demand for prefillable products enabled by capacity expansion.

      In BD Life Sciences, revenue growth reflects strong performance in the base business in the Integrated Diagnostic Solutions (IDS) and Biosciences units.  Growth in the base business in IDS reflects continued recovery in demand for specimen management products and microbiology solutions.  Performance in the Biosciences unit reflects demand for research solutions as lab activity continued to normalize.  COVID-19 diagnostic testing revenue in IDS declined to $316 million from $452 million in the prior year.

      In BD Interventional, revenue growth in the Surgery and Peripheral Intervention units reflects the recovery in deferrable procedure volumes compared to the prior year, despite pressures from the Delta variant.  Performance in the Surgery unit reflects growth across our biosurgery, infection prevention and hernia platforms.  Growth in the Peripheral Intervention unit reflects continued strong performance in atherectomy and oncology.  Performance in the Urology and Critical Care unit was driven by continued strong demand for acute urology products and the targeted temperature management portfolio.

      Capital Allocation
      BD is committed to a balanced capital allocation strategy that includes competitive investments in Research & Development, a competitive and increasing dividend and additional capacity to create value through tuck-in acquisitions, and potential share repurchases, while maintaining full investment grade credit ratings.

      During the fourth quarter of fiscal year 2021, BD repurchased 3.0 million shares at a total cost of $750 million. 

      BD announced its 50th year of dividend increases, raising its dividend 4.8%.  Additionally, the Board of Directors authorized the company to repurchase up to 10 million shares of its common stock, which is in addition to the approximately 0.8 million shares that remain on its existing authorization.

      Recent Business Highlights
      BD continues to advance an innovation-driven growth strategy. Recent highlights include:

      • BD FACSymphony™ A1 Cell Analyzer: a new fluorescence-activated cell analyzer that offers advanced research capabilities in a compact design, and helps improve access to instrumentation for complex scientific research for laboratories of all sizes. 
      • BD COR™ System: a new, fully automated high-throughput molecular diagnostic platform that uses robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core and other centralized laboratories in the U.S.  The launch will make the BD Onclarity™ HPV Assay with extended genotyping for the BD COR™ System available to the high-throughput labs that process the majority of cervical cancer screening specimens in the U.S.
      • BD Veritor™ At-Home COVID-19 Test: BD received Emergency Use Authorization for the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results. 
      • Rotarex™ Rotational Excisional Atherectomy System: 510(k) clearance received for expanded indications; The Rotarex™ System is the first and only atherectomy and thrombectomy device indicated to treat in-stent restenosis in the U.S.

      Recent Environmental, Social and Governance (ESG) Highlights
      BD recently announced its enhanced ESG strategy, Together We Advance, which serves as a framework through which the company addresses the most relevant ESG issues for itself and its stakeholders.  The new approach builds on BD's core Purpose – advancing the world of health™ – and focuses on making meaningful impacts across four key pillars: impacting the health of the company, planet, communities and people.

      • Under Together We Advance, BD announced a suite of goals for 2030 and beyond across Climate Change, Product Impacts, Responsible Supply Chain, Healthy Workforce and Communities, and Transparency.
      • BD joined the Race to Zero, the largest alliance dedicated to achieving net zero carbon emissions by 2050.
      • BD, together with the BD Foundation, continued their commitment to help U.S. community health centers expand health equity among the nation's most vulnerable patients through monetary grants awarded to six community health centers that provide quality care to underinsured and uninsured patients.

      Assumptions and Outlook for Full Year Fiscal 2022
      BD's outlook for fiscal 2022 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date, which includes assumptions regarding the continued recovery from the COVID-19 pandemic.  The company's outlook continues to assume no major system-wide hospital restrictions on elective procedures related to the COVID-19 pandemic.  Management will discuss its outlook and several of its assumptions on its fourth fiscal quarter earnings call.

      The company expects fiscal year 2022 revenues to be in the range of $19.3 to $19.5 billion.  Revenue guidance assumes base business currency-neutral revenue growth of 5% to 6%, which reflects continued momentum across our businesses driven by our BD 2025 growth strategy and continued recovery from the COVID-19 pandemic.  In addition, the revenue guidance range assumes approximately $200 million in COVID-19-only diagnostic testing revenues.  Based on current rates, foreign exchange would represent a headwind of approximately 50 basis points to total company revenue growth. 

      The company expects fiscal year 2022 adjusted diluted EPS to be $12.30 to $12.50.

      The company's expected adjusted diluted EPS for fiscal 2022 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin-off related charges, and certain tax matters.  BD does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.  In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors.  Such items could have a substantial impact on GAAP measures of BD's financial performance.

      Conference Call and Presentation Materials
      A conference call regarding BD's fourth quarter results will be broadcast live on BD's website, www.bd.com/investors at 8 a.m. (ET) Thursday, November 4, 2021.  The accompanying slides will be available on BD's website, www.bd.com/investors at 6 a.m. (ET).  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-839-1246 (domestic) and 1-402-220-0464 (international) through the close of business on Thursday, Nov. 11, 2021.  A confirmation number is not needed to access the replay.

      Non-GAAP Financial Measures/Financial Tables
      This news release contains certain non-GAAP financial measures.  These include revenue growth rates on a currency-neutral basis and adjusted diluted earnings per share.  These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.  BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our base operating results, and understand future prospects.  Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing such results to previous periods or forecasts.  We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison for other companies within the medical technology industry.  Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP.  Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations.  BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures.  Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

      Current, prior-quarter and prior-year adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments, integration and restructuring costs, spin-off related charges, certain transaction gains, certain legal defense and product remediation costs, certain regulatory costs, certain investment gains and asset impairments and the impact of the extinguishment of debt.

      We also provide these measures, as well as revenues, on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable.  We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results.

      Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

      About BD
      BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.  The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.  BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues.  By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.  For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

      ***

      This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues and earnings per share and capital deployment.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially.  These factors include, but are not limited to, risks relating to any impact of the current disruptions in the global supply chain on our operations, including our ability to source raw materials and components needed to manufacture our products and inflationary pressures, the possible impact of the COVID-19 pandemic on our business (including decreases in the demand for our products, any disruptions to our operations and our supply chain, and factors such as vaccine utilization rates and competitive factors that could impact the demand and pricing for our COVID-19 diagnostics testing); product efficacy or safety concerns resulting in product recalls or actions being taken with respect to our products; new or changing laws and regulations impacting our business (including the imposition of tariffs, changes in tax laws, new environmental laws and regulations, or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; fluctuations in costs and availability of raw materials, labor shortages or increased labor costs and BD's ability to maintain favorable supplier arrangements and relationships; legislative or regulatory changes to the U.S. or foreign healthcare systems, potential cuts in governmental healthcare spending (including China's volume-based procurement tender process) or governmental or private measures to contain healthcare costs, including changes in pricing and reimbursement policies, each of which could result in reduced demand for our products or downward pricing pressure; changes in interest or foreign currency exchange rates; adverse changes in regional, national or foreign economic conditions, including inflation, deflation and fluctuations in interest rates, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations; the demand for our products and services, or our suppliers' ability to provide products needed for our operations; the adverse impact of cyber-attacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; risks relating to our overall indebtedness; interruptions in our supply chain, manufacturing or sterilization processes; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; adverse changes in geopolitical conditions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; the remediation of our infusion pump business (including risks relating to our ability to obtain regulatory clearance and market acceptance of the BD Alaris™ System); our ability to achieve our projected level or mix of product sales; our ability to successfully integrate any businesses we acquire; uncertainties of litigation and/or investigations and/or subpoenas (as described in BD's filings with the Securities and Exchange Commission); and the issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  In addition, we have made certain assumptions in making these forward-looking statements, particularly regarding the COVID-19 pandemic.  If any of these assumptions are incorrect, BD's actual results could differ materially from those described in these forward-looking statements. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

      BECTON DICKINSON AND COMPANY

      CONSOLIDATED INCOME STATEMENTS

      (Unaudited; Amounts in millions, except share and per share data)




      Three Months Ended September 30,



      2021


      2020


      % Change

      REVENUES


      $

      5,135


      $

      4,784


      7.3








      Cost of products sold


      2,848


      2,578


      10.5

      Selling and administrative expense


      1,332


      1,200


      11.0

      Research and development expense


      387


      299


      29.4

      Acquisitions and other restructurings


      59


      75


      (21.4)

      Other operating expense, net


      14


      378


      (96.2)

      TOTAL OPERATING COSTS AND EXPENSES


      4,640


      4,529


      2.4

      OPERATING INCOME


      495


      254


      94.6








      Interest expense


      (111)


      (123)


      (10.3)

      Interest income


      2


      2


      3.3

      Other (expense) income, net


      (120)


      10


      (1,249.7)

      INCOME BEFORE INCOME TAXES


      266


      143


      85.6

      Income tax provision


      1


      16


      (91.7)

      NET INCOME


      265


      128


      107.5

      Preferred stock dividends


      (23)


      (23)


      (1.1)

      NET INCOME APPLICABLE TO COMMON SHAREHOLDERS


      $

      242


      $

      105


      131.1








      EARNINGS PER SHARE







      Basic Earnings per Share


      $

      0.85


      $

      0.36


      136.1

      Diluted Earnings per Share


      $

      0.84


      $

      0.36


      133.3








      AVERAGE SHARES OUTSTANDING (in thousands)







      Basic


      285,985


      290,348



      Diluted


      288,598


      293,328



      BECTON DICKINSON AND COMPANY

      CONSOLIDATED INCOME STATEMENTS

      (Unaudited; Amounts in millions, except share and per share data)










      Twelve Months Ended September 30,



      2021


      2020


      % Change

      REVENUES


      $

      20,248


      $

      17,117


      18.3








      Cost of products sold


      10,821


      9,540


      13.4

      Selling and administrative expense


      4,867


      4,325


      12.5

      Research and development expense


      1,339


      1,096


      22.2

      Acquisitions and other restructurings


      185


      309


      (40.3)

      Other operating expense, net


      238


      363


      (34.5)

      TOTAL OPERATING COSTS AND EXPENSES


      17,449


      15,633


      11.6

      OPERATING INCOME


      2,799


      1,484


      88.6








      Interest expense


      (469)


      (528)


      (11.3)

      Interest income


      9


      7


      22.0

      Other (expense) income, net


      (97)


      23


      (526.5)

      INCOME BEFORE INCOME TAXES


      2,242


      985


      127.6

      Income tax provision


      150


      111


      35.0

      NET INCOME


      2,092


      874


      139.4

      Preferred stock dividends


      (90)


      (107)


      (15.9)

      NET INCOME APPLICABLE TO COMMON SHAREHOLDERS


      $

      2,002


      $

      767


      161.1








      EARNINGS PER SHARE







      Basic Earnings per Share


      $

      6.92


      $

      2.75


      151.6

      Diluted Earnings per Share


      $

      6.85


      $

      2.71


      152.8








      AVERAGE SHARES OUTSTANDING (in thousands)







      Basic


      289,288


      278,971



      Diluted


      292,089


      282,402










      BECTON DICKINSON AND COMPANY

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in millions)




      September 30, 2021


      September 30, 2020



      (Unaudited)
      Preliminary



      ASSETS





      Cash and equivalents


      $

      2,283


      $

      2,825

      Restricted cash


      109


      92

      Short-term investments


      12


      20

      Trade receivables, net


      2,497


      2,398

      Inventories


      2,866


      2,743

      Prepaid expenses and other


      1,072


      891

      TOTAL CURRENT ASSETS


      8,838


      8,969

      Property, plant and equipment, net


      6,393


      5,923

      Goodwill and other intangibles, net


      36,684


      37,433

      Other Assets


      1,952


      1,687

      TOTAL ASSETS


      $

      53,866


      $

      54,012

      LIABILITIES AND SHAREHOLDERS' EQUITY





      Short-term debt


      $

      500


      $

      707

      Other current liabilities


      6,126


      5,129

      Long-term debt


      17,110


      17,224

      Long-term employee benefit obligations


      1,228


      1,435

      Deferred income taxes and other liabilities


      5,225


      5,753

      Shareholders' equity


      23,677


      23,765

      TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY


      $

      53,866


      $

      54,012


      The preliminary balance sheet is estimated based on the Company's current information.

      BECTON DICKINSON AND COMPANY

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (Amounts in millions)




      Twelve Months Ended September 30,



      2021


      2020



      (Unaudited)
      Preliminary



      OPERATING ACTIVITIES





      Net income


      $

      2,092


      $

      874

      Depreciation and amortization


      2,273


      2,154

      Change in operating assets and liabilities and other, net


      282


      512

      NET CASH PROVIDED BY OPERATING ACTIVITIES


      4,647


      3,539

      INVESTING ACTIVITIES





      Capital expenditures


      (1,231)


      (810)

      Acquisitions, net of cash acquired


      (508)


      (164)

      Other, net


      (142)


      (257)

      NET CASH USED FOR INVESTING ACTIVITIES


      (1,880)


      (1,232)

      FINANCING ACTIVITIES





      Change in credit facility borrowings


      —


      (485)

      Proceeds from long-term debt and term loans


      4,869


      3,389

      Payments of debt and term loans


      (5,112)


      (4,664)

      Proceeds from issuance of equity securities


      —


      2,917

      Repurchases of common stock


      (1,750)


      —

      Dividends paid


      (1,048)


      (1,026)

      Other, net


      (265)


      (109)

      NET CASH (USED FOR) PROVIDED BY FINANCING ACTIVITIES


      (3,306)


      22

      Effect of exchange rate changes on cash and equivalents and restricted cash


      15


      (3)

      NET (DECREASE) INCREASE IN CASH AND EQUIVALENTS AND
      RESTRICTED CASH


      (525)


      2,326

      OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH


      2,917


      590

      CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH


      $

      2,392


      $

      2,917


      The preliminary cash flow is estimated based on the Company's current information.

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

      Three Months Ended September 30,

      (Unaudited; Amounts in millions)




      A


      B


      C=(A-B)/B



      2021


      2020


      % Change

      BD MEDICAL







      Medication Delivery Solutions


      $

      587


      $

      522


      12.4

      Medication Management Solutions


      487


      453


      7.4

      Diabetes Care


      156


      145


      7.6

      Pharmaceutical Systems


      136


      117


      17.0

      TOTAL


      $

      1,366


      $

      1,236


      10.5








      BD LIFE SCIENCES







      Integrated Diagnostic Solutions


      $

      573


      $

      729


      (21.4)

      Biosciences


      138


      112


      23.1

      TOTAL


      $

      711


      $

      841


      (15.5)








      BD INTERVENTIONAL







      Surgery


      $

      266


      $

      232


      14.9

      Peripheral Intervention


      238


      230


      3.6

      Urology and Critical Care


      222


      212


      4.6

      TOTAL


      $

      727


      $

      674


      7.8








      TOTAL UNITED STATES


      $

      2,803


      $

      2,752


      1.9

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

      Three Months Ended September 30, (continued)

      (Unaudited; Amounts in millions)










      D=(A-B)/B


      E=(A-B-C)/B



      A


      B


      C


      % Change



      2021


      2020


      FX Impact


      Reported


      FXN

      BD MEDICAL











      Medication Delivery Solutions


      $

      457


      $

      400


      $

      18


      14.3


      9.7

      Medication Management Solutions


      153


      181


      5


      (15.5)


      (18.5)

      Diabetes Care


      140


      132


      4


      6.2


      3.1

      Pharmaceutical Systems


      416


      369


      8


      12.8


      10.8

      TOTAL


      $

      1,166


      $

      1,081


      $

      35


      7.8


      4.6












      BD LIFE SCIENCES











      Integrated Diagnostic Solutions


      $

      607


      $

      455


      $

      17


      33.2


      29.4

      Biosciences


      214


      191


      4


      12.0


      9.6

      TOTAL


      $

      821


      $

      647


      $

      22


      26.9


      23.6












      BD INTERVENTIONAL











      Surgery


      $

      70


      $

      54


      $

      2


      29.3


      24.9

      Peripheral Intervention


      191


      170


      7


      12.4


      8.1

      Urology and Critical Care


      84


      80


      2


      4.3


      1.7

      TOTAL


      $

      345


      $

      304


      $

      12


      13.3


      9.4












      TOTAL INTERNATIONAL


      $

      2,331


      $

      2,032


      $

      69


      14.7


      11.3

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

      Three Months Ended September 30, (continued)

      (Unaudited; Amounts in millions)










      D=(A-B)/B


      E=(A-B-C)/B



      A


      B


      C


      % Change



      2021


      2020


      FX Impact


      Reported


      FXN

      BD MEDICAL











      Medication Delivery Solutions


      $

      1,043


      $

      921


      $

      18


      13.3


      11.3

      Medication Management Solutions


      639


      634


      5


      0.9


      0.1

      Diabetes Care


      297


      277


      4


      6.9


      5.4

      Pharmaceutical Systems


      553


      485


      8


      13.8


      12.3

      TOTAL


      $

      2,532


      $

      2,318


      $

      35


      9.2


      7.7












      BD LIFE SCIENCES











      Integrated Diagnostic Solutions


      $

      1,180


      $

      1,185


      $

      17


      (0.4)


      (1.9)

      Biosciences


      352


      303


      4


      16.1


      14.6

      TOTAL


      $

      1,532


      $

      1,488


      $

      22


      2.9


      1.5












      BD INTERVENTIONAL











      Surgery


      $

      336


      $

      286


      $

      2


      17.6


      16.8

      Peripheral Intervention


      429


      399


      7


      7.4


      5.5

      Urology and Critical Care


      306


      293


      2


      4.5


      3.8

      TOTAL


      $

      1,071


      $

      978


      $

      12


      9.5


      8.3












      TOTAL REVENUES


      $

      5,135


      $

      4,784


      $

      69


      7.3


      5.9

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

      Twelve Months Ended September 30,

      (Unaudited; Amounts in millions)










      A


      B


      C=(A-B)/B



      2021


      2020


      % Change

      BD MEDICAL







      Medication Delivery Solutions


      $

      2,246


      $

      1,972


      13.9

      Medication Management Solutions


      1,863


      1,865


      (0.1)

      Diabetes Care


      606


      562


      7.8

      Pharmaceutical Systems


      428


      404


      6.1

      TOTAL


      $

      5,142


      $

      4,802


      7.1








      BD LIFE SCIENCES







      Integrated Diagnostic Solutions


      $

      2,477


      $

      1,872


      32.3

      Biosciences


      503


      465


      8.2

      TOTAL


      $

      2,980


      $

      2,337


      27.5








      BD INTERVENTIONAL







      Surgery


      $

      1,023


      $

      891


      14.8

      Peripheral Intervention


      931


      871


      6.8

      Urology and Critical Care


      894


      815


      9.7

      TOTAL


      $

      2,847


      $

      2,577


      10.5








      TOTAL UNITED STATES


      $

      10,969


      $

      9,716


      12.9








      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

      Twelve Months Ended September 30, (continued)

      (Unaudited; Amounts in millions)




















      D=(A-B)/B


      E=(A-B-C)/B



      A


      B


      C


      % Change



      2021


      2020


      FX Impact


      Reported


      FXN

      BD MEDICAL











      Medication Delivery Solutions


      $

      1,812


      $

      1,583


      $

      86


      14.4


      9.0

      Medication Management Solutions


      570


      589


      35


      (3.3)


      (9.3)

      Diabetes Care


      554


      522


      24


      6.2


      1.6

      Pharmaceutical Systems


      1,401


      1,184


      66


      18.3


      12.7

      TOTAL


      $

      4,336


      $

      3,878


      $

      211


      11.8


      6.4












      BD LIFE SCIENCES











      Integrated Diagnostic Solutions


      $

      2,748


      $

      1,659


      $

      134


      65.6


      57.5

      Biosciences


      802


      678


      35


      18.3


      13.1

      TOTAL


      $

      3,550


      $

      2,337


      $

      169


      51.9


      44.6












      BD INTERVENTIONAL











      Surgery


      $

      274


      $

      230


      $

      14


      19.0


      12.7

      Peripheral Intervention


      780


      640


      45


      21.8


      14.8

      Urology and Critical Care


      338


      315


      16


      7.4


      2.2

      TOTAL


      $

      1,392


      $

      1,186


      $

      75


      17.4


      11.1












      TOTAL INTERNATIONAL


      $

      9,279


      $

      7,401


      $

      456


      25.4


      19.2












      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL REVENUE INFORMATION

      REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

      Twelve Months Ended September 30, (continued)

      (Unaudited; Amounts in millions)




















      D=(A-B)/B


      E=(A-B-C)/B



      A


      B


      C


      % Change



      2021


      2020


      FX Impact


      Reported


      FXN

      BD MEDICAL











      Medication Delivery Solutions


      $

      4,057


      $

      3,555


      $

      86


      14.1


      11.7

      Medication Management Solutions


      2,432


      2,454


      35


      (0.9)


      (2.3)

      Diabetes Care


      1,160


      1,084


      24


      7.0


      4.8

      Pharmaceutical Systems


      1,829


      1,588


      66


      15.2


      11.1

      TOTAL


      $

      9,479


      $

      8,680


      $

      211


      9.2


      6.8












      BD LIFE SCIENCES











      Integrated Diagnostic Solutions


      $

      5,225


      $

      3,532


      $

      134


      47.9


      44.1

      Biosciences


      1,305


      1,143


      35


      14.2


      11.1

      TOTAL


      $

      6,530


      $

      4,675


      $

      169


      39.7


      36.1












      BD INTERVENTIONAL











      Surgery


      $

      1,296


      $

      1,121


      $

      14


      15.7


      14.4

      Peripheral Intervention


      1,711


      1,511


      45


      13.2


      10.2

      Urology and Critical Care


      1,232


      1,130


      16


      9.0


      7.6

      TOTAL


      $

      4,239


      $

      3,762


      $

      75


      12.7


      10.7












      TOTAL REVENUES


      $

      20,248


      $

      17,117


      $

      456


      18.3


      15.6












      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL INFORMATION

      RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

      (Unaudited)




      Three Months Ended September 30,



      2021


      2020


      Growth


      Foreign
      Currency
      Translation


      Foreign
      Currency
      Neutral
      Growth


      Growth %


      Foreign
      Currency
      Neutral
      Growth %

      Reported Diluted Earnings per Share


      $

      0.84


      $

      0.36


      $

      0.48


      $

      (0.02)


      $

      0.50


      133.3%


      138.9%

      Purchase accounting adjustments ($350 million and $343 million pre-tax, respectively) (1)


      1.21


      1.17











      Integration costs ($41 million and $49 million pre-tax, respectively) (2)


      0.14


      0.17











      Restructuring costs ($17 million and $26 million pre-tax, respectively) (2)


      0.06


      0.09











      Separation and related costs ($19 million pre-tax) (3)


      0.07


      —











      Transaction gain/loss, product and other litigation-related matters ($13 million and $383 million pre-tax, respectively) (4)


      0.05


      1.31











      European regulatory initiative-related costs ($43 million and $29 million pre-tax, respectively) (5)


      0.15


      0.10











      Investment gains/losses and asset impairments ($(46) million and $59 million pre-tax, respectively) (6)


      (0.16)


      0.20











      Impacts of debt extinguishment ($154 million and $1 million pre-tax, respectively)


      0.53


      —











      Income tax benefit of special items ($(88) million and $(177) million, respectively)


      (0.30)


      (0.60)











      Adjusted Diluted Earnings per Share


      $

      2.59


      $

      2.79


      $

      (0.20)


      $

      (0.02)


      $

      (0.18)


      (7.2)%


      (6.5)%




      (1)

      Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt.

      (2)

      Represents amounts associated with integration and restructuring activities resulting from acquisitions, as well as simplification and other cost saving initiatives.

      (3)

      Represents costs recorded to Other operating expense, net which were incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business.

      (4)

      The 2021 amount includes a gain of $70 million on a sale-leaseback transaction which was recorded to Other operating expense, net and charges of $18 million recorded to Cost of products sold related to the estimate of future product remediation costs. The amounts in 2021 and 2020 also include amounts recorded to Other operating expense, net to record product liability reserves, including related legal defense costs, of $65 million and $378 million, respectively.

      (5)

      Represents costs required to develop processes and systems to comply with regulations such as the European Union Medical Device Regulation ("EUMDR") and General Data Protection Regulation ("GDPR").

      (6)

      The amount in 2021 includes unrealized gains recorded within Other (expense) income, net relating to certain investments. The amount in 2020 includes charges recorded in Cost of products sold and Research and development expense to write down the carrying values of certain assets.

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL INFORMATION

      RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

      (Unaudited)


















      Twelve Months Ended September 30,



      2021


      2020


      Growth


      Foreign
      Currency
      Translation


      Foreign
      Currency
      Neutral
      Growth


      Growth %


      Foreign
      Currency
      Neutral
      Growth %

      Reported Diluted Earnings per Share


      $

      6.85


      $

      2.71


      $

      4.14


      $

      (0.05)


      $

      4.19


      152.8%


      154.6%

      Purchase accounting adjustments ($1.406 billion and $1.356 billion pre-tax, respectively) (1)


      4.82


      4.80




      0.01







      Integration costs ($135 million and $214 million pre-tax, respectively) (2)


      0.46


      0.76











      Restructuring costs ($50 million and $95 million pre-tax, respectively) (2)


      0.17


      0.33











      Separation and related costs ($35 million pre-tax) (3)


      0.12


      —











      Transaction gain/loss, product and other litigation-related matters ($272 million and $631 million pre-tax, respectively) (4)


      0.93


      2.24











      European regulatory initiative-related costs ($135 million and $106 million pre-tax, respectively) (5)


      0.46


      0.38











      Investment gains/losses and asset impairments ($(46) million and $100 million pre-tax, respectively) (6)


      (0.16)


      0.35











      Impacts of debt extinguishment ($185 million and $8 million pre-tax, respectively)


      0.63


      0.03











      Income tax benefit of special items ($(353) million and $(395) million, respectively)


      (1.21)


      (1.40)











      Adjusted Diluted Earnings per Share


      $

      13.08


      $

      10.20


      $

      2.88


      $

      (0.04)


      $

      2.92


      28.2%


      28.6%




      (1)

      Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt.

      (2)

      Represents amounts associated with integration and restructuring activities resulting from acquisitions, as well as simplification and other cost saving initiatives.

      (3)

      Represents costs recorded to Other operating expense, net which were incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business.

      (4)

      The 2021 amount includes gains of $158 million on sale-leaseback transactions. The amounts in 2021 and 2020 include charges to record product liability reserves, including related legal defense costs, of $361 million and $378 million, respectively. The sale-leaseback gains and product liability-related charges were recorded to Other operating expense, net. The amounts in 2021 and 2020 also include charges of $56 million and $244 million, respectively, recorded to Cost of products sold related to the estimate of future product remediation costs.

      (5)

      Represents costs required to develop processes and systems to comply with regulations such as the EUMDR and GDPR.

      (6)

      The amount in 2021 includes unrealized gains recorded within Other (expense) income, net relating to certain investments. The prior-period amount includes charges recorded in Cost of products sold and Research and development expense to write down the carrying values of certain assets.

      BECTON DICKINSON AND COMPANY

      SUPPLEMENTAL INFORMATION

      FY 2022 OUTLOOK RECONCILIATION










      Full Year FY2021


      Full Year FY2022 Outlook



      ($ in millions)


      FX Neutral % Change


      Reported Revenues

      BDX Reported Revenues


      $

      20,248





      Less: COVID-19-only Diagnostic Testing Revenues


      1,956





      Base Business Revenues


      $

      18,292












      FY2022 Base Business Revenue Growth




      +5% to +6%



      FY2022 COVID-19-only Diagnostic Testing Revenues






      ~$200 million

      Illustrative Foreign Currency (FX) Impact, based on FX spot rates






      (~50) basis points

      Total FY 2022 Revenues






      $19.3 - $19.5 billion







      Full Year FY2022 Outlook



      Full Year FY2021


      Total Company

      Reported Diluted Earnings per Share


      $

      6.85



      Purchase accounting adjustments ($1.406 billion pre-tax) (1)


      4.82



      Integration costs ($135 million pre-tax) (2)


      0.46



      Restructuring costs ($50 million pre-tax) (2)


      0.17



      Separation and related costs ($35 million pre-tax) (3)


      0.12



      Transaction gain/loss, product and other litigation-related matters ($272 million pre-tax) (4)


      0.93



      European regulatory initiative-related costs ($135 million pre-tax) (5)


      0.46



      Investment gains/losses and asset impairments ($(46) million pre-tax) (6)


      (0.16)



      Impacts of debt extinguishment ($185 million pre-tax)


      0.63



      Income tax benefit of special items ($(353) million)


      (1.21)



      Adjusted Diluted Earnings per Share


      $

      13.08


      $12.30 to $12.50





      Note - Base Business Revenues denotes total revenues less estimated revenues for COVID-19 only diagnostic testing



      (1)

      Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt.

      (2)

      Represents amounts associated with integration and restructuring activities resulting from acquisitions, as well as simplification and other cost saving initiatives.

      (3)

      Represents costs recorded to Other operating expense, net which were incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business.

      (4)

      Includes gains of $158 million on sale-leaseback transactions and charges of $361 million to record product liability reserves, including related legal defense costs, which were recorded to Other operating expense, net. The amount also includes charges of $56 million recorded to Cost of products sold related to the estimate of future product remediation costs.

      (5)

      Represents costs required to develop processes and systems to comply with regulations such as the EUMDR and GDPR.

      (6)

      Includes unrealized gains recorded within Other (expense) income, net relating to certain investments.


      Contact:
      Investors: Nadia Goncalves, BD Investor Relations - 201-847-5934
      Media: Troy Kirkpatrick, BD Public Relations - 858-617-2361

      SOURCE BD (Becton, Dickinson and Company)

      Modal title

      Also from this source

      BD Marks 85 Years of Essential Medical Device Manufacturing in Glens Falls, NY

      BD Marks 85 Years of Essential Medical Device Manufacturing in Glens Falls, NY

      BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrates the 85th anniversary of its...

      BD Named to TIME's 2027 List of America's Top Manufacturers

      BD Named to TIME's 2027 List of America's Top Manufacturers

      BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has been named to TIME's 2027 list of America's Top...

      More Releases From This Source

      Explore

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.